In some cases such as advanced melanoma, the presence of a BRAF mutation actually improves patient prognostic outlook [123], while in other types such as colorectal cancer, the finding of a BRAF V600E mutation is associated with resistance to standard therapy and is overall a biomarker of poor prognosis [124]. The gene discussed is BRAF; the disease is melanoma.